ELI LILLY AND COMPANY Depreciation
ELI LILLY AND COMPANY (LLY) reported Depreciation of $1.31 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-12
- ELI LILLY AND COMPANY depreciation for the quarter ending 2015-06-30 was $216.60M, a 0.14% increase year-over-year.
- ELI LILLY AND COMPANY depreciation for the quarter ending 2014-06-30 was $216.30M.
- ELI LILLY AND COMPANY depreciation for fiscal 2025 was $1.31B, a 24.20% increase from fiscal 2024.
- ELI LILLY AND COMPANY depreciation for fiscal 2024 was $1.06B, a 17.29% increase from fiscal 2023.
- ELI LILLY AND COMPANY depreciation for fiscal 2023 was $902.00M, a 10.46% increase from fiscal 2022.
- ELI LILLY AND COMPANY depreciation for fiscal 2022 was $816.60M, a 3.76% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $1.31B 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $1.06B 10-K · filed 2026-02-12 | |||
| 2023-12-31 | $902.00M 10-K · filed 2026-02-12 | $901.90M 10-K · filed 2024-02-21 | ||
| 2022-12-31 | $816.60M 10-K · filed 2025-02-19 | |||
| 2021-12-31 | $787.00M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $765.20M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $814.70M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | $797.10M 10-K · filed 2021-02-17 | $879.60M 10-K · filed 2019-02-19 | ||
| 2017-12-31 | $681.70M 10-K · filed 2020-02-19 | $763.10M 10-K · filed 2018-02-20 | ||
| 2016-12-31 | $638.80M 8-K · filed 2019-10-24 | $716.20M 10-K · filed 2017-02-21 | ||
| 2015-12-31 | $717.60M 10-K · filed 2018-02-20 | |||
| 2015-06-30 | $216.60M 10-Q · filed 2015-07-30 | $421.40M 10-Q · filed 2015-07-30 | ||
| 2014-12-31 | $759.10M 10-K · filed 2017-02-21 | |||
| 2014-06-30 | $216.30M 10-Q · filed 2015-07-30 | $436.30M 10-Q · filed 2015-07-30 | ||
| 2013-12-31 | $774.80M 10-K · filed 2016-02-19 | |||
| 2012-12-31 | $754.00M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | $732.40M 10-K · filed 2014-02-19 | |||
| 2010-12-31 | $749.10M 10-K · filed 2013-02-21 | |||
| 2009-12-31 | $813.50M 10-K · filed 2012-02-24 | |||
| 2008-12-31 | $731.70M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |